Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs
July 30th 2025
By Cameron Santoro
ArticlePatients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.